Female androgen insufficiency: the princeton consensus statement on definition, classification, and assessment

Bachmann, Gloria; Bancroft, John; Braunstein, Glenn D.; Burger, Henry G.; Davis, Susan Ruth; Dennerstein, Lorraine; Goldstein, Irwin; Guay, André T.; Leiblum, Sandra R.; Løbo, Rogerio A.; Notelovitz, Morris; Rosen, Raymond C.; Sarrel, Philip M.; Sherwin, Barbara B.; Simon, James A.; Simpson, Evan R.; Shifren, Jan; Spark, Richard F.; Traish, Abdul

doi:10.1016/s0015-0282(02)02969-2

Cited by 391 publications

(293 citation statements)

References 13 publications

Supporting

Mentioning

259

Contrasting

Unclassified

Order By: Relevance

“…Uma conferência internacional de especialistas denominada Consenso de Princeton, realizada com o propósito de revisar a literatura pertinente e avaliar as evidências favoráveis e contrárias à insuficiência androgênica feminina, enunciou o seguinte conceito de SIA: "A síndrome da insuficiência androgênica na mulher constitui-se num conjunto de sintomas clínicos na presença de biodisponibilidade diminuída de testosterona e níveis normais de estrogênios" (Bachmann et al, 2002).…”

Section: A Deficiência Androgênica Em Mulheresunclassified

“…Entre estes, o proposto pelo consenso de Princeton, que apresentamos com algumas modificações, parece bastante apropriado (Figura 4) (Bachmann et al, 2002).…”

Section: Figuraunclassified

“…Há muitos anos reconhece-se o papel dos esteróides sexuais, em particular dos estrogênios e dos androgênios, na Figura 4. Roteiro semiótico para o diagnóstico da síndrome da insuficiência androgênica feminina, segundo o consenso de Princeton (Bachmann et al, 2002). Observar que não existe consenso quanto às dosagens laboratoriais para a comprovação da deficiência androgênica.…”

Section: Androgênios E Sexualidade Femininaunclassified

See 2 more Smart Citations

Síndrome de insuficiência androgênica: critérios diagnósticos e terapêuticos

Fernandes¹,

Rennó

Nahás³

et al. 2006

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

ResumoA síndrome da insuficiência androgênica na mulher (SIA) desperta, mesmo nos dias atuais, muitas discussões e encerra muitas controvérsias. Sabe-se, no entanto, que os níveis plasmáticos de testosterona declinam progressivamente ao longo do período reprodutivo. Conceitua-se a SIA como o conjunto de sintomas clínicos, a presença de biodisponibilidade diminuída de testosterona e os níveis normais de estrogênios. Entre os principais sintomas, citam-se o comprometimento do bem-estar, o humor disfórico, a fadiga sem causa aparente, o comprometimento do desejo sexual, o emagrecimento e a instabilidade vasomotora em mulheres pós-menopáusicas sob terapêutica estrogênica. Esses sintomas, no entanto, são potencialmente atribuíveis a diferentes etiologias e dificultam o correto diagnóstico na maioria dos casos, ainda que ele seja lembrado com freqüência em pacientes que se submetem à ooforectomia bilateral. O diagnóstico da SIA parece ser essencialmente clínico, não havendo a necessidade das dosagens laboratoriais para a sua comprovação. Não se deve indicar a terapêutica androgênica (TA) em pacientes que não estejam adequadamente estrogenizadas. Considera-se a testosterona o hormônio ideal para a TA. As pacientes com sintomas sugestivos de SIA, excluídas outras causas identificáveis, especialmente se pós-menopáusicas, são candidatas à TA. Não existem dados de segurança sobre a TA em usuárias em longo prazo. A via transdérmica -através de adesivos, cremes e gel -parece ser preferível à oral.Palavras-chave: Deficiência androgênica, terapêutica androgênica, disfunção sexual feminina.

show abstract

Section: A Deficiência Androgênica Em Mulheresunclassified

“…Entre estes, o proposto pelo consenso de Princeton, que apresentamos com algumas modificações, parece bastante apropriado (Figura 4) (Bachmann et al, 2002).…”

Section: Figuraunclassified

Section: Androgênios E Sexualidade Femininaunclassified

See 1 more Smart Citation

Síndrome de insuficiência androgênica: critérios diagnósticos e terapêuticos

Fernandes¹,

Rennó

Nahás³

et al. 2006

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

show abstract

“…Androgens, including testosterone (T), are believed to play a key role in sexual function and mood, and androgen replacement therapy, such as transdermal testosterone, has been shown to improve symptoms such as well-being, mood and sexual desire in pre-and postmenopausal women with sexual dysfunction [14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects

Zimmerman¹,

Foidart²,

Pintiaux³

et al. 2015

Contraception

View full text Add to dashboard Cite

Source of fundingThe study was financially supported by Pantarhei Bioscience Conflict of interestYZ is an employee of Pantarhei Bioscience (PRB), the company developing the Androgen RestoredContraceptive concept for contraception. JMF has no conflict of interest in the course of this study.AP shares expertise as a lecturer, member of advisory boards, and/or consultant, with Bayer, Amgen, Gedeon Richter and Teva/Theramex, without personal gain. JMM has nothing to declare. KC has nothing to declare. BF has received fees and grant support from the following companies (in alphabetic order); Andromed, Ardana, Euroscreen, Ferring, Genovum, Merck (MSD), Merck Serono, Organon, Ovascience, Pantharei Bioscience, PregLem, Schering, Schering Plough, Serono, Uteron Pharma, Watson Pharmaceuticals and Wyeth. HCB is the CEO and a shareholder of PRB.After publication of the paper, PRB will make the clinical study report available upon request. The authors alone are responsible for the content and the writing of the paper. Clinical Trial Registration Number: ISRCTN06414473A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT AbstractObjectives: Combined oral contraceptives (COCs) decrease androgen levels, including testosterone (T), which may be associated with sexual dysfunction and mood complaints in some women. We have shown that co-administration of dehydroepiandrosterone (DHEA) to a drospirenone (DRSP) containing COC restored total T levels to baseline and free T levels by 47%. Here we describe the effects on sexual function, mood and quality of life of such an intervention. Study design:This was a randomized, double-blind, placebo-controlled study in 99 healthy COC starters. A COC containing 30 µg ethinylestradiol (EE) and 3 mg DRSP was used for 3 cycles, followed by 6 cycles of the same COC combined with 50 mg/day DHEA or placebo. There were no statistically significant differences between groups for the MSFQ and Q-LES-Q scores. DHEA co-administration resulted in an acceptable safety profile. DHEA negated the beneficial effect of the COC on acne according to the subjects' self-assessment. A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPTConclusions: Co-administration with DHEA did not result in consistent improvements in sexual function, mood and quality of life indicators in women taking EE/DRSP.Retrospectively, the 50 mg dose of DHEA may be too low for this COC.Implications A well-balanced judgment of the clinical consequences of normalizing androgens during COC use may require complete normalization of free T.

show abstract

“…Furthermore, other conditions can also result in ethanol and also hyperthyroidism, pregnancy and liver cirrhosis 2 . This is because, by increasing levels of sex hormone binding globulin (SHBG), they can reduce free androgen levels 3 .…”

Section: Introductionmentioning

confidence: 99%

Deficiência androgênica na mulher

Fonseca¹,

Scapinelli²,

Aoki³

et al. 2010

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

The evidence suggest that androgen deficiency in women induces sexual dysfunction as its main clinical manifestation, in particular reduced libido. However, other factors may be involved in the genesis of this disease, such as interpersonal relationships, social stressors, physical inactivity and the partner. The prevalence of sexual problems among women ranges from 9 to 43% and, recently, many studies have reported that androgens are beneficial not only for women's sexual function, but also for mood disorders and vasomotor symptoms. This is why physicians should include androgen deficiency syndrome in their differential diagnosis, even in women with adequate estrogen levels. Our objective was to present the practical aspects of this disease, emphasizing diagnosis and focusing on treatment. This review searched PUBMED for publications from the last 51 years, up to May 2010, including consensus statements and expert opinions and identified 105 articles. We concluded that the androgen deficiency syndrome in women is overlooked in clinical practice. There is no consensus in the literature regarding diagnosis or treatment, including choice of drug, route of administration and time of application.

show abstract

Female androgen insufficiency: the princeton consensus statement on definition, classification, and assessment

Cited by 391 publications

References 13 publications

Síndrome de insuficiência androgênica: critérios diagnósticos e terapêuticos

Síndrome de insuficiência androgênica: critérios diagnósticos e terapêuticos

Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects

Deficiência androgênica na mulher

Contact Info

Product

Resources

About